RE:RE:RE:RE:Delay in Phase 1 a --------Get over it What you are actually talking about is OBSERVABLE Sortilin. If you have a very poor observation tool then you may score a patient as having no Sortilin when in fact you have low Sortilin which is below the detectable level. So it is possible to have an affect in a patient with no observable Sortilin because there is actually enough Sortilin to produce an affect you just can't see it with the tool you are using.
That's a roundabout way to say you don't move forward on assumptions, you do it through observations. All-comers in a sense is an explicit rejection of assumption. It's an opportunity to set no enrolment rule about Sortilin levels and to learn something about the drug because of that.
Daiichi's HER2 ADC appears to work in a much broader range of HER2 expression levels compared to the antibody it's based on. They know this not through making assumptions but by testing it on patients. THTX has to go through the same testing process to learn the limits of it's drug.
https://www.medpagetoday.com/meetingcoverage/sabcs/96154
LouisW wrote: My assumption is.....Patient 2 and 4 moved to 1.5x were because they are SORT1 positive patients. If they are not SORT1 positive, no need to treat more.